Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuraxis (NRXS) Cash & Equivalents (2022 - 2025)

Historic Cash & Equivalents for Neuraxis (NRXS) over the last 4 years, with Q3 2025 value amounting to $4.4 million.

  • Neuraxis' Cash & Equivalents rose 157779.25% to $4.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.4 million, marking a year-over-year increase of 157779.25%. This contributed to the annual value of $3.7 million for FY2024, which is 460579.18% up from last year.
  • Per Neuraxis' latest filing, its Cash & Equivalents stood at $4.4 million for Q3 2025, which was up 157779.25% from $6.0 million recorded in Q2 2025.
  • In the past 5 years, Neuraxis' Cash & Equivalents registered a high of $6.0 million during Q2 2025, and its lowest value of $51440.0 during Q2 2023.
  • Over the past 4 years, Neuraxis' median Cash & Equivalents value was $761249.0 (recorded in 2023), while the average stood at $1.8 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first tumbled by 6903.42% in 2023, then skyrocketed by 460579.18% in 2024.
  • Over the past 4 years, Neuraxis' Cash & Equivalents (Quarter) stood at $253699.0 in 2022, then plummeted by 69.03% to $78560.0 in 2023, then surged by 4605.79% to $3.7 million in 2024, then grew by 18.4% to $4.4 million in 2025.
  • Its Cash & Equivalents stands at $4.4 million for Q3 2025, versus $6.0 million for Q2 2025 and $2.0 million for Q1 2025.